Journal
JOURNAL OF INFECTION
Volume 57, Issue 2, Pages 103-109Publisher
W B SAUNDERS CO LTD
DOI: 10.1016/j.jinf.2008.06.007
Keywords
tuberculosis; biomarker discovery; surrogate marker; treatment response; relapse
Categories
Ask authors/readers for more resources
Currently the ultimate success of anti-TB therapy is measured by the relapse rate within the first 2 years after treatment. The tong duration of clinical trials that rely on this outcome constitute a disincentive for the pharmaceutical industry to develop new TB drugs. Biomarkers for relapse measurable during early treatment may shorten clinical trials. Additionally pre-treatment markers could allow stratification of patients into groups with different treatment requirements for improved clinical management. Currently there is a lack of sufficiently validated biomarkers with good individual predictive value and an urgent need for candidate markers and their evaluation in prospective studies. This review provides an overview of novel biomarkers for TB treatment response and outcome focusing on immunological markers in serum. Additionally, the challenges and roadblocks biomarker research is currently faced with are highlighted. (c) 2008 The British Infection Society. Published by Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available